Infant formula supplemented with milk fat globule membrane compared with standard infant formula for the cognitive development of healthy term-born formula-fed infants: protocol for a randomised controlled trial

• Published in: BMJ open 2024-07, Vol.14 (6), p.e083399
• Main Authors: Gould, Jacqueline F, Gibson, Robert A, Yelland, Lisa N, Colombo, John, McPhee, Andrew J, Gallier, Sophie, Roberts, Rachel M, Shaddy, D. Jill, Bednarz, Jana, Makrides, Maria
• Format: Article
• Language: English
• Subjects: Age; Babies; Baby foods; Breast Feeding; Breastfeeding & lactation; Caregivers; Child Development; Cognition & reasoning; Cognition - drug effects; Cognitive ability; Cognitive development; Consent; Developmental neurology & neurodisability; Dietary Supplements; Families & family life; Female; Glycolipids - administration & dosage; Glycoproteins - administration & dosage; Humans; Immune system; Infant; Infant Formula - chemistry; Infant, Newborn; Lipid Droplets; Male; Medical research; Milk; Milk, Human - chemistry; NUTRITION & DIETETICS; Oils & fats; Paediatrics; Pediatrics; Randomized Controlled Trial; Randomized Controlled Trials as Topic; Womens health
• ISSN: 2044-6055; 2044-6055
• DOI: 10.1136/bmjopen-2023-083399

IntroductionMilk fat globule membrane (MFGM) is a complex lipid–protein structure in mammalian milk and human milk that is largely absent from breastmilk substitutes. The objective of this trial is to investigate whether providing infant formula enriched with MFGM versus standard infant formula improves cognitive development at 12 months of age in exclusively formula-fed full-term infants.Methods and analysisThis is a randomised, controlled, clinician-blinded, researcher-blinded and participant-blinded trial of two parallel formula-fed groups and a breastfed reference group that were recruited in the suburban Adelaide (Australia) community by a single study centre (a medical research institute). Healthy, exclusively formula-fed, singleton, term-born infants under 8 weeks of age were randomised to either an MFGM-supplemented formula (intervention) or standard infant formula (control) from enrolment until 12 months of age. The reference group was not provided with formula. The primary outcome is the Cognitive Scale of the Bayley Scales of Infant Development, Fourth Edition (Bayley-IV) at 12 months. Secondary outcomes are the Bayley-IV Cognitive Scale at 24 months, other Bayley-IV domains (language, motor, emotional and behavioural development) at 12 and 24 months of age, infant attention at 4 and 9 months of age, parent-rated language at 12 and 24 months of age, parent-rated development at 6 and 18 months of age as well as growth, tolerance and safety of the study formula. To ensure at least 80% power to detect a 5-point difference in the mean Bayley-IV cognitive score, >200 infants were recruited in each group.Ethics and disseminationThe Women’s and Children Health Network Human Research Ethics Committee reviewed and approved the study (HREC/19/WCHN/140). Caregivers gave written informed consent prior to enrolling in the trial. Findings of this study will be disseminated through peer-reviewed publications and conference presentations.Trial registration numberACTRN12620000552987; Australian and New Zealand Clinical Trial Registry: anzctr.org.au.